Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

@article{Till2008AdoptiveIF,
  title={Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.},
  author={B. Till and M. Jensen and Jinjuan Wang and Eric. Y. Chen and B. Wood and H. Greisman and Xiaojun Qian and S. James and A. Raubitschek and S. Forman and A. Gopal and J. Pagel and C. Lindgren and P. Greenberg and S. Riddell and O. Press},
  journal={Blood},
  year={2008},
  volume={112 6},
  pages={
          2261-71
        }
}
  • B. Till, M. Jensen, +13 authors O. Press
  • Published 2008
  • Medicine
  • Blood
  • Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma in human subjects. We report the results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific… CONTINUE READING
    577 Citations

    Paper Mentions

    The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
    • 8
    Treatment of lymphoma with adoptively transferred T cells
    • 17
    Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma
    • 2

    References

    SHOWING 1-10 OF 53 REFERENCES
    Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
    • 87
    Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    • 464
    Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    • 1,516
    • PDF
    Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
    • 2,724